Merck agrees with Cell Biotech exclusive distribution of probiotics products in Spain and Portugal

Merck Farma y Química has reached an agreement with cell biotech europe to distribute exclusively at Spain and Portugal probiotics products of new generation. Continuing with its strategy of offering the market innovative products and high quality standards, Merck has signed this agreement that will allow you to further strengthen its portfolio of biotechnology products based on its high bioavailability and efficacy. The company will market and develop projects based on probiotics of fourth generation whose advanced peptide encapsulation technique allows to maintain intact than as beneficial bacteria are to the body.

Probiotics are bacteria responsible for the balance of the digestive system, to be effective in the treatment and prevention of pathologies such as syndrome of irritable bowel, ulcerative colitis, Crohn's disease, colon cancer, diarrheainfections of the urinary tract and heart disease. Thanks to its properties also contribute to strengthen the immune system and to alleviate problems such as high levels of cholesterol, halitosis, side effects of antibiotics, food poisoning, indigestion or lactose intolerance. To enjoy all its benefits, probiotics are incorporated into food or administered food under different presentations, such as envelopes, untimely supplements, capsules, tablets, chewable, drops, granules, or chewing gum.

Cell Biotech is a company in continuous production, fermentation and encapsulation of probiotics research patented under DoulacTM technologies. This technology allows a correct functionality to prevent that the bacteria are destroyed by stomach acids and bile acids. Cell Biotech and Merck launch also on the market the new "Bacteriocins" based on peptides patented, safe and selective (LactopadTM, SafelacTM, LactocinTM, Prolac-TTM,...) that offer bacteriostatic control of bacterial pathogens for the treatment of conditions for both new cosmetic applications anti-acné.